Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug be tailored for japanese patients? a new trial seeks answers

NCT ID NCT07723118

Not yet recruiting Knowledge-focused Sponsor: Mirati Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This early-stage study is testing how a single dose of the experimental cancer drug adagrasib is processed by the body in 10 healthy adults of Japanese descent. Researchers will measure drug levels in the blood and monitor for any side effects. The goal is to gather safety and pharmacokinetic data to guide future studies in Japanese patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a single dose of the experimental cancer drug adagrasib (BMS-986503)
What this could lead to
If successful, this study could help determine the right dosing of adagrasib for Japanese patients in future trials.
What could go wrong
This is a very early, small study in only 10 healthy people, so results may not predict effects in patients or broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Local Institution - 0001

    Anaheim, California, 92801, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.